Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
14.08
+0.10 (+0.72%)
Official Closing Price
Updated: 4:10 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
Next >
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Today 8:30 EDT
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 11, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
April 09, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
April 06, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
April 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
April 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
February 26, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
February 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Growth in Fourth Quarter and Full Year 2023
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
January 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
December 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
December 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
MarketBeat Week in Review – 11/27 - 12/1
December 02, 2023
Stocks closed the week at or near yearly highs after subdued inflation numbers suggest the Federal Reserve will continue to pause on raising rates
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
November 28, 2023
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
Via
MarketBeat
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
November 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.